CAMP Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
1.8M
+37.5%
1.3M
+271.8%
348.0K
-56.2%
795.0K
-46.9%
1.5M
Cost of Revenue
0
0
0
0
0
Gross Profit
1.8M
+37.5%
1.3M
+271.8%
348.0K
-56.2%
795.0K
-46.9%
1.5M
Operating Expenses
15.2M
+5.5%
14.4M
+9.5%
13.1M
-9.2%
14.4M
-0.5%
14.5M
R&D
10.8M
+6.5%
10.2M
+21.6%
8.4M
-10.7%
9.4M
-9.5%
10.3M
SG&A
4.3M
+3.3%
4.2M
-11.8%
4.8M
+3.7%
4.6M
+9.9%
4.2M
Operating Income
-13380000
-2.4%
-13071000
-2.3%
-12776000
+6.4%
-13651000
-4.8%
-13028000
EBITDA
-12865000
-2.5%
-12551000
-1.2%
-12404000
+2.6%
-12741000
-1.1%
-12598000
Net Income
-33530000
-82.9%
-18331000
+54.5%
-40284000
-166.8%
-15099000
-20.0%
-12587000
EPS (Basic)
$-0.58
-81.2%
$-0.32
+57.3%
$-0.75
-36.4%
$-0.55
+11.3%
$-0.62
EPS (Diluted)
$-0.58
-81.2%
$-0.32
+57.3%
$-0.75
-36.4%
$-0.55
+11.3%
$-0.62
Shares (Diluted)
57.9M
+0.0%
57.9M
+7.4%
53.9M
+97.7%
27.3M
+35.3%
20.2M
CAMP4 Therapeutics (CAMP) โ€” Financials